Growth hormone and proinflammatory cytokine activation in heart failure. Just a new verse to an old sirens' song?

European Heart Journal

Volumn 24, Issue 24, 2003, Pages 2164-2165

  Wollert, Kai C ^a   Drexler, Helmut ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELL ADHESION MOLECULE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH HORMONE; IMMUNOLOGIC AGENT; INTERLEUKIN 6; MACROPHAGE CHEMOTACTIC FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTAGONIST; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFECT; EDITORIAL; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE WALL; HEART VENTRICLE HYPERTROPHY; HORMONAL THERAPY; HORMONE ACTION; HUMAN; INFLAMMATION; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPATHETIC TONE; TREATMENT OUTCOME;

CROSS-OVER STUDIES; CYTOKINES; GROWTH HORMONE; HEART FAILURE, CONGESTIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 0346328577     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2003.10.016     Document Type: Editorial

References (17)

1. McMurray JJ, Ostersren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
2. Demers C, McKelvie RS. Growth hormone therapy in heart failure: where are we now? Congest Heart Fail 2003;9:84-90.
3. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
4. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation 2000;102:IV14-23.
5. Dorn GW 2nd, Robbins J, Sudden PH. Phenotyping hypertrophy: eschew obfuscation. Circ Res 2003;92:1171-5.
6. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569-82.
7. Fazio S, Sabatini D, Capaldo B et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996;334:809-14.
8. Osterziel KJ, Strohm O, Schuler J et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998;351:1233-7.
9. Houck WV, Pan LC, Kribbs SB et al. Effects of growth hormone supplementation on left ventricular morphology and myocyte function with the development of congestive heart failure. Circulation 1999;100:2003-9.
10. Tajima M, Weinberg EO, Bartunek J et al. Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. Circulation 1999;99:127-34.
11. Dalla Libera L, Ravara B, Volterrani M et al. Beneficial Effects of GH/IGF-1 on Skeletal Muscle Atrophy and Function in Experimental Heart Failure. Am J Physiol Cell Physiol in press.
12. Napoli R, Guardasole V, Matarazzo M et al. Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J Am Coll Cardiol 2002;39:90-5.
13. Adamopoulos S, Parissis JT, Paraskevaidis I et al. Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy. Eur Heart J 2003;24:2186-96.
14. Coletta AP, Clark AL, Banarjee P et al. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail 2002;4:559-61.
15. Wollert KC, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev 2001;6:95-103.
16. Mann DL. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol 2003;65:81-101.
17. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002;91:988-98.